Shares of Moderna, Inc. (NASDAQ:MRNA - Get Free Report) saw an uptick in trading volume on Monday . 3,565,164 shares were traded during trading, a decline of 24% from the previous session's volume of 4,701,348 shares.The stock last traded at $37.86 and had previously closed at $36.85.
Analysts Set New Price Targets
A number of research firms recently issued reports on MRNA. Sanford C. Bernstein began coverage on Moderna in a research note on Thursday, October 17th. They set a "market perform" rating and a $55.00 price objective on the stock. JPMorgan Chase & Co. decreased their price objective on Moderna from $70.00 to $59.00 and set an "underweight" rating on the stock in a research note on Monday, November 4th. Bank of America decreased their price objective on Moderna from $130.00 to $110.00 and set a "neutral" rating on the stock in a research note on Friday, September 13th. Leerink Partners decreased their price objective on Moderna from $60.00 to $48.00 and set an "underperform" rating on the stock in a research note on Tuesday, September 17th. Finally, The Goldman Sachs Group decreased their price objective on Moderna from $178.00 to $139.00 and set a "buy" rating on the stock in a research note on Monday, September 16th. Three equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Moderna currently has an average rating of "Hold" and a consensus target price of $86.33.
Check Out Our Latest Research Report on MRNA
Moderna Price Performance
The business has a fifty day moving average price of $58.56 and a 200-day moving average price of $96.68. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $15.20 billion, a PE ratio of -6.70 and a beta of 1.69.
Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to analysts' expectations of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company's revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.39) EPS. Research analysts expect that Moderna, Inc. will post -9.43 EPS for the current fiscal year.
Insider Activity at Moderna
In related news, CFO James M. Mock sold 1,321 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. This represents a 13.32 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold 2,930 shares of company stock worth $217,170 in the last ninety days. 15.70% of the stock is owned by company insiders.
Institutional Investors Weigh In On Moderna
Several institutional investors have recently bought and sold shares of MRNA. Avantax Advisory Services Inc. raised its position in Moderna by 53.3% during the 1st quarter. Avantax Advisory Services Inc. now owns 5,035 shares of the company's stock valued at $537,000 after purchasing an additional 1,750 shares during the last quarter. O Shaughnessy Asset Management LLC raised its position in Moderna by 40.8% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 10,869 shares of the company's stock valued at $1,158,000 after purchasing an additional 3,148 shares during the last quarter. UniSuper Management Pty Ltd raised its position in Moderna by 307.7% during the 1st quarter. UniSuper Management Pty Ltd now owns 13,158 shares of the company's stock valued at $1,402,000 after purchasing an additional 9,931 shares during the last quarter. Bessemer Group Inc. raised its position in Moderna by 4.0% during the 1st quarter. Bessemer Group Inc. now owns 7,258 shares of the company's stock valued at $774,000 after purchasing an additional 276 shares during the last quarter. Finally, Lake Street Advisors Group LLC bought a new position in Moderna during the 1st quarter valued at approximately $398,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.
Moderna Company Profile
(
Get Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Further Reading
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
